We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cytogen Announces FDA Clears IND for CYT-500
News

Cytogen Announces FDA Clears IND for CYT-500

Cytogen Announces FDA Clears IND for CYT-500
News

Cytogen Announces FDA Clears IND for CYT-500

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cytogen Announces FDA Clears IND for CYT-500 "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cytogen Corporation has announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for CYT-500, the company's lead therapeutic candidate targeting prostate-specific membrane antigen (PSMA).

Cytogen expects to begin the first U.S. Phase I clinical trial of CYT-500 in patients with hormone-refractory prostate cancer subject to Institutional Review Board (IRB) approval at the planned clinical site.

CYT-500 uses the same monoclonal antibody from Cytogen's ROSTASCINT® (capromab pendetide) molecular imaging agent, but is linked through a higher affinity linker than is used for PROSTASCINT to a therapeutic as opposed to an imaging radionuclide.

This product candidate is designed to enable targeted delivery of a cytotoxic agent to PSMA-expressing cells. Cytogen retains full and exclusive development rights to CYT-500.

"This regulatory clearance by the FDA is an important step in our efforts to develop CYT-500," stated Michael D. Becker, president and chief executive officer of Cytogen.

"In a very short period of time, we have produced clinical quality drug and have received regulatory clearance to proceed with clinical trials, which we expect to initiate soon after IRB approval."

"As a pioneer in PSMA-related research and development, these are significant steps forward for Cytogen that expand our focus on developing and commercializing novel therapeutic oncology products."

Advertisement